Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PsiloIMAGINE: Psilocybin-augmented Mental Imagery-based Intervention for Self-harm
NCT06798636Phase 1Recruiting
- Sponsor
- Imperial College London
- Start
- Oct 2025
- Primary completion
- Aug 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised trial in self-harm (NSSI) comparing Psilocybin 5mg with Placebo (2 arms). Primary endpoints: Frequency of mental imagery at 3 months, Vividness of mental imagery at 3 months and 3 more. Started Oct 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
self-harm (NSSI)
Beyond the preview
Go deeper on NCT06798636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06798636.